Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis

被引：30

作者：

Jallades, Laurent ^{[1
]}

Hayette, Sandrine ^{[1
,3
]}

Tigaud, Isabelle ^{[1
]}

Johnston, Anna ^{[2
]}

Coiffier, Bertrand ^{[2
,3
]}

Magaud, Jean-Pierre ^{[1
,3
]}

Ffrench, Martine ^{[1
,2
,3
]}

机构：

[1] Ctr Hosp Lyon Sud, Hematol Lab, F-69310 Pierre Benite, France

[2] Ctr Hosp Lyon Sud, Serv Hematol, F-69310 Pierre Benite, France

[3] Univ Lyon 1, CNRS, Fac Lyon Sud, UMR ENS UCB HCL 5239, Oullins, France

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 10期

关键词：

chronic myeloid leukemia; JAK2; chronic idiopathic myelofibrosis;

D O I：

10.1016/j.leukres.2008.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report the emergence of a chronic myeloid leukaemia (CML) during the course of a JAK2V617F-positive chronic idiopathic myelofibrosis (CIMF) in the absence of any myelosuppressive treatment. Although a response to imatinib was observed, the underlying myelofibrosis persisted after treatment and hydroxyurea was finally added to control the persistent thrombocytosis. Such rare patients with co-existing BCR-ABL translocation and JAK2V617F mutation must be identified in view of the possibility of targeted therapies. Moreover, the detection of BCR-ABL translocation appears to be crucial especially in the case of treated CIMF with an atypical course to identify CML before acute transformation. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1608 / 1610

页数：3

共 7 条

[1]

Bocchia M, 2007, LANCET ONCOL, V8, P864, DOI 10.1016/S1470-2045(07)70295-4

[2] The Philadelphia translocation and pre-existing myeloproliferative disorders [J].

Curtin, NJ ;

Campbell, PJ ;

Green, AR .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) :734-736

[3] Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation [J].

Hussein, Kais ;

Bock, Oliver ;

Seegers, Anna ;

Flasshove, Michael ;

Henneke, Felicitas ;

Buesche, Guntram ;

Kreipe, Hans Heinrich .

BLOOD, 2007, 109 (09) :4106-4107

[4] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[5] JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia [J].

Jelinek, J ;

Oki, Y ;

Gharibyan, V ;

Bueso-Ramos, C ;

Prchal, JT ;

Verstovsek, S ;

Beran, M ;

Estey, E ;

Kantarjian, HM ;

Issa, JPJ .

BLOOD, 2005, 106 (10) :3370-3373

[6]

Mirza I, 2007, ARCH PATHOL LAB MED, V131, P1719

[7] Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis [J].

Traverse-Glehen, A. ;

Verney, A. ;

Baseggio, L. ;

Felman, P. ;

Callet-Bauchu, E. ;

Thieblemont, C. ;

Ffrench, M. ;

Magaud, J-P ;

Coiffier, B. ;

Berger, F. ;

Salles, G. .

LEUKEMIA, 2007, 21 (08) :1824-1826

← 1 →